We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 02, 2020

Ribociclib Plus Fulvestrant With or Without a PI3K Inhibitor for HR+ Advanced Breast Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Clin. Cancer Res 2020 Oct 12;[EPub Ahead of Print], SM Tolaney, YH Im, E Calvo, YS Lu, E Hamilton, A Forero-Torres, T Bachelot, M Maur, A Fasolo, R Tiedt, L Nardi, U Stammberger, AM Abdelhady, S Ruan, SC Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading